Panagora Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-66,554
| Closed | -$123K | – | 1543 |
|
|
2023
Q1 | $123K | Buy |
66,554
+26,467
| +66% | +$32.8K | ﹤0.01% | 1407 |
|
|
2022
Q4 | $44.5K | Sell |
40,087
-104,200
| -72% | -$148K | ﹤0.01% | 1421 |
|
|
2022
Q3 | $338K | Buy |
144,287
+36,172
| +33% | +$128K | ﹤0.01% | 1245 |
|
|
2022
Q2 | $328K | Sell |
108,115
-15,236
| -12% | -$74.1K | ﹤0.01% | 1288 |
|
|
2022
Q1 | $838K | Buy |
123,351
+10,286
| +9% | +$73.3K | ﹤0.01% | 1010 |
|
|
2021
Q4 | $944K | Buy |
113,065
+7,369
| +7% | +$60.7K | 0.01% | 952 |
|
|
2021
Q3 | $785K | Buy |
105,696
+12,829
| +14% | +$79.5K | ﹤0.01% | 1081 |
|
|
2021
Q2 | $631K | Buy |
92,867
+91,500
| +6,693% | +$760K | ﹤0.01% | 1234 |
|
|
2021
Q1 | $14K | Hold |
1,367
| – | – | ﹤0.01% | 2353 |
|
|
2020
Q4 | $10K | Sell |
1,367
-1,530
| -53% | -$11.9K | ﹤0.01% | 2301 |
|
|
2020
Q3 | $24K | Buy |
2,897
+664
| +30% | +$4.12K | ﹤0.01% | 2169 |
|
|
2020
Q2 | $15K | Sell |
2,233
-1,003
| -31% | -$5.41K | ﹤0.01% | 2190 |
|
|
2020
Q1 | $15K | Hold |
3,236
| – | – | ﹤0.01% | 2096 |
|
|
2019
Q4 | $28K | Hold |
3,236
| – | – | ﹤0.01% | 1998 |
|
|
2019
Q3 | $11K | Buy |
3,236
+2,617
| +423% | +$10.5K | ﹤0.01% | 2162 |
|
|
2019
Q2 | $3K | Buy |
+619
| New | +$3.29K | ﹤0.01% | 2521 |
|
|
2017
Q3 | – | Sell |
-581
| Closed | -$8K | – | 2547 |
|
|
2017
Q2 | $8K | Sell |
581
-5,832
| -91% | -$125K | ﹤0.01% | 2487 |
|
|
2017
Q1 | $141K | Buy |
+6,413
| New | +$136K | ﹤0.01% | 1765 |
|
Other funds holding JNCE
Panagora Asset Management's JNCE Position: Q2 2023 in Review
Panagora Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 66,554 shares — an estimated $123K sold.
Panagora Asset Management first reported a position in JNCE in Q1 2017 and held it in 18 quarters. The position peaked at $944K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Panagora Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Panagora Asset Management sold 66,554 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $123K.
- Panagora Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 18 quarters.
- Panagora Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $944K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Panagora Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.